文献速递前列腺癌

转移性去势抵抗性前列腺癌同源重组基因缺陷患者对铂类化疗的反应差异

Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
PubMed 文献 · J Urol · 2021-04-27

该回顾性研究纳入55例多西他赛进展后接受铂类化疗的mCRPC患者,对14个同源重组(HR)通路基因进行基因组分析。HR缺陷组中位PSA-PFS为6.7个月,显著长于无HR缺陷组的2.6个月(p=0.001);BRCA2或ATM缺陷患者PSA50反应率(6/8,75.0%)高于CDK12缺陷患者(2/9,22.2%;p=0.06)。多因素分析显示HR缺陷及BRCA2或ATM缺陷是铂类化疗PSA-PFS更优的独立因素。

要点

  • HR缺陷组中位PSA-PFS 6.7个月,优于无HR缺陷组的2.6个月(p=0.001)。
  • BRCA2或ATM缺陷者PSA50反应率75.0%,高于CDK12缺陷者的22.2%(p=0.06)。
  • BRCA2或ATM缺陷者PSA-PFS优于CDK12缺陷及其他HR缺陷者(p=0.038)。

核心结论

  • mCRPC患者中不同HR基因缺陷对铂类化疗反应存在差异,BRCA2或ATM缺陷者可能获益更优。

研究设计与样本

  • 回顾性研究,纳入55例多西他赛化疗进展后接受铂类化疗的mCRPC患者,对14个HR通路基因进行基因组分析。

主要发现

  • 55例中23例携带HR通路基因缺陷。
  • HR缺陷组中位PSA-PFS为6.7个月,无HR缺陷组为2.6个月(p=0.001)。
  • 体细胞HR缺陷者PSA-PFS短于胚系HR缺陷者(4.5个月 vs 不可评估;p=0.066)。
  • BRCA2或ATM缺陷者PSA50反应率为6/8(75.0%),CDK12缺陷者为2/9(22.2%;p=0.06)。
  • BRCA2或ATM缺陷者PSA-PFS优于CDK12缺陷及其他HR缺陷者(p=0.038)。

关键数值与推荐

  • 多因素Cox回归显示HR缺陷及BRCA2或ATM缺陷是铂类化疗PSA-PFS更优的独立显著因素。

临床怎么用

  • 对mCRPC患者进行HR通路基因检测,尤其关注BRCA2、ATM和CDK12状态,可能有助于筛选铂类化疗潜在获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We aimed to explore the association between genomic status and clinical outcome of platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer (mCRPC). MATERIALS AND METHODS: We conducted a retrospective study of 55 patients with mCRPC who received platinum-based chemotherapy after the progression to docetaxel chemotherapy and underwent genomic profiling of 14 homologous recombination (HR) pathway genes. Progression-free survival (PFS) was analyzed using the Kaplan-Meier method. RESULTS: Of 55 patients, 23 harbored genomic defects in HR pathway genes. Median prostate specific antigen (PSA)-PFS for the HR defect group was 6.7 months compared with 2.6 months for the no HR defect group (p=0.001). The patients harboring somatic HR defect displayed shorter PSA-PFS than those harboring germline HR defect (4.5 months vs not available; p=0.066). The PSA50 (patients who survived for 12 weeks and had a PSA decline over 50% from baseline) response rate displayed higher in patients harboring BRCA2 or ATM defect (6/8, 75.0%) than in those harboring CDK12 defect (2/9, 22.2%; p=0.06). Patients harboring BRCA2 or ATM defect displayed prolonged PSA-PFS, compared with those harboring CDK12 defect and those harboring other HR defect (p=0.038). In multivariate Cox regression analysis, HR defect and BRCA2 or ATM defect were independent significant factors associated with superior PAS-PFS to platinum-based chemotherapy. CONCLUSIONS: The patients with mCRPC harboring alterations in different HR genes displayed distinct response to platinum-based chemotherapy. Patients with mCRPC harboring genomic defects in crucial HR genes either in the germline or somatic, especially BRCA2 and ATM, might experience superior outcomes to platinum-based chemotherapy, compared with those harboring CDK12 defect.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Fan L, Fei X, Zhu Y, et al. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination. J Urol. 2021. PMID: 33904759. doi:10.1097/JU.0000000000001819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。